ARCA biopharma Inc
ABIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.5B
Close$
$2.58
91.1% downside
Current Fair Value
91.1% downsideOvervalued by 91.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.50 Billion |
|---|---|
| Enterprise Value | $5.23 Billion |
| Dividend Yield | $1.61 (-) |
| Earnings per Share | $-154.03 |
| Beta | 0.9 |
| Outstanding Shares | 62,872 |
Return
| Return on Equity | -11.92% |
|---|---|
| Return on Assets | -11.66% |
| Return on Invested Capital | -13.89% |
Valuation & Multiples
| P/E Ratio | -36.9 |
|---|---|
| PEG | -54.52 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -33.73 |
| Enterprise Value to Net Income | -40 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Oruka Therapeutics, Inc.
28 employees
CEO: Dr. Lawrence Otto Klein Ph.D. Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.